Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin

Samsung Medical Center100 enrolled

Overview

In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.

To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Curatively Resected Stage III Colon Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * aged 18 or older * curatively resected colon adenocarcinoma * pathologically staged III * adequate performance status * adequate major organ functions * to be treated with adjuvant FOLFOX chemotherapy * written informed consent Exclusion Criteria: * those who disagree the study

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

neuropathy

Time frame: six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.